SCHEMBL425555

SCHEMBL425555

Cc1ccc(OC2CCN(C(=O)n3cnc(-c4ccc(F)cc4F)n3)CC2)cc1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.43
HRH1 P35367 1/20 0.39
CCR3 P51677 1/20 0.39
EPHX2 P34913 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CHRNA7 P36544 3/20 0.37
GRIN2D O15399 2/20 0.37
GRIN3B O60391 2/20 0.37
GRIN1 Q05586 2/20 0.37
GRIN2A Q12879 2/20 0.37
GRIN2B Q13224 2/20 0.37
GRIN2C Q14957 2/20 0.37
GRIN3A Q8TCU5 2/20 0.37
ACACB O00763 1/20 0.37
ADRB2 P07550 1/20 0.37
FPR2 P25090 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427532 0.76 HDAC6 (0.49)
SCHEMBL424352 0.75 MEN1 (0.48) FAAHCCR3MEN1KMT2A
SCHEMBL424468 0.75 MAP4K1 (0.42) HRH1EPHX2MEN1KMT2AFPR2
SCHEMBL461673 0.73 CHRM4 (0.38)
SCHEMBL2636897 0.67 EPHX2 (0.60) HRH1CCR3EPHX2MEN1KMT2A
SCHEMBL16220677 0.67 EPHX2 (0.56) HRH1CCR3EPHX2CHRNA7GRIN2D
SCHEMBL7903565 0.66 AKR1C3 (0.48) MEN1KMT2A
SCHEMBL4577471 0.66 EPHX2 (0.58) HRH1CCR3EPHX2MEN1KMT2A
SCHEMBL2366320 0.65 ALDH1A1 (0.54) MEN1KMT2A
SCHEMBL14311593 0.65 EPHX2 (0.57) HRH1CCR3EPHX2KMT2ACHRNA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885HRH1 45/4885CCR3 1217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.